ECLP Eclipsys Corp. (MM)

Eclipsys Corporation (NASDAQ:ECLP), The Outcomes Company®, today announced its response to the Center for Medicare and Medicaid Services’(CMS) final rule on ‘meaningful use’ of an electronic health records (EHR). Countering opinions describing any criteria to include Computerized Provider Order Entry (CPOE) in 2011 as “too ambitious,” Eclipsys applauds CMS for coming forward to add electronic medication order entry as a requirement for achieving “meaningful use.” According to the final rule regulation, at least 30 percent of patients with a medication order must have that order entered through a CPOE solution. Moreover, in Stage 2 of ‘meaningful use,’ scheduled for 2013, the CPOE medication order requirement doubles to 60 percent. A sole focus on CPOE related to patient medication is a significant change from the interim final rule CPOE requirement of 10 percent of orders, regardless of order type.

“The addition of medication order entry as a requirement will directly support patient safety, clinical decision support and decrease the risk of medication errors that daily impacts the lives and well-being of patients and their families,” said Phil Pead, president and chief executive officer. “What’s important to note is that the landmark Institute of Medicine report, ‘To Err is Human,’ was published 11 years ago, calling for expanded use of CPOE to reduce avoidable medical errors and deaths. The passage of the CMS’ Electronic Health Record Incentive Program is an unprecedented opportunity to move forward the quality and safety of care for all of us. As a leading provider of health care technology, we know meaningful CPOE adoption is achievable and we strongly support this effort to expedite implementing a technology that prevents human errors and has been proven to reduce costs, injuries and deaths.”

In additional response to the ‘meaningful use’ final rule, Eclipsys also supports:

• The retention of quality measures defined by data collected in the EHR vs. quality measures defined based on claims data. This strategy aligns with the company’s commitment to analytics & performance management embedded in workflow of clinicians.
• The inclusion of the emergency department orders in achieving the CPOE 30 percent threshold. It is a realistic approach given the reality of today’s hospital workflow with many patients being admitted through this area of the hospital.

A Client Base That Already Exceeds the CPOE Meaningful Use Threshold

Eclipsys response to fully supporting the 30 percent CPOE requirement is backed by its experience in supporting swift and “deep” CPOE adoption by clients across the nation. The company estimates its U.S. client base has achieved on average a 70 percent CPOE adoption rate. In fact, Eclipsys is noted in the industry as having the most physicians and the highest percentage of its own client base deeply using CPOE, including use to support advancements in complex cancer treatment regimens, reduced medication errors, hospital-acquired conditions and improved perioperative procedures — all of which otherwise present harm to patients and added costs to the nation’s healthcare delivery system. For example, select Eclipsys clients have successfully optimized CPOE to achieve the following outcomes:

• A 69 percent reduction in sepsis-related mortalities;
• A 59.2 percent drop in medication-related errors reaching patients;
• A 1.0 day reduction in length of stay in patients undergoing sternotomy, as well as a 70 percent reduction in mediastinitis infection rate.

Further commenting Pead said, “Hospitals waste millions of dollars every year through inefficient paper processes, which ironically often leave medication errors undetected. The personal experiences shared during this week’s CMS’ live press conference by HHS Secretary Sebelius, Surgeon General Regina Benjamin and Regina Holiday are evidence that the problem of medication errors within our healthcare system is very real, very costly and it is avoidable — especially knowing that Eclipsys clients across the country already are in the position to meet and far exceed the meaningful use provisions both in 2011 and 2013.”

A Client Base Ranked No. 1 in Meeting Composite CMS Quality Measures; Dominates Magnet Hospitals

In addition to CPOE adoption, the Eclipsys client base outperforms industry peers on multiple fronts. Eclipsys’ clinical information system clients dominate the field of Magnet Recognition Program® hospitals. Magnet status provides consumers with a benchmark to measure the quality of care they can expect to receive. Eclipsys clients represent 45 percent of all organizations receiving Magnet status. The company’s clients also represent more than 80 percent of the organizations listed as “America’s Best Hospitals,” according to the U.S. News & World Report’s 2009 ranking. Further, Eclipsys clients account for eight of the top 10 U.S. health systems and 27 of the top 51 health systems based on their clinical performance across the entire system according to the June 2010 Thomson Reuters study.

Client Webinar Scheduled

Eclipsys will host an educational client webinar on Friday, July 16, at 11 a.m. Eastern Time, entitled “Final Ruling on Meaningful Use of EHR and its Impact on You.” The webinar will focus on final ruling updates and how clients can leverage Sunrise Enterprise™ 5.5 to help their organization achieve meaningful use. Eclipsys clients can register at https://swrt.worktankseattle.com/webcast/5089/preview.aspx

About the Final Rule

On July 13, 2010, CMS issued the much–anticipated final rule on ‘Meaningful Use. The information technology regulations establish the requirements that eligible professionals and hospitals must adhere to in order to fully meet requirements for financial incentives authorized under the HITECH ACT of the American Recovery & Reinvestment Act (ARRA) of 2009. The final rule was accompanied by one on certification and standards from the Office of the National Coordinator for Healthcare IT. The final federal register version of the regulation will be issued on July 28, 2010. For more information, see http://www.cms.gov/EHRIncentivePrograms/

The CMS EHR Incentive Program Final rule can be found at: http://www.ofr.gov/OFRUpload/OFRData/2010-17207_PI.pdf

The ONC Standards, Implementation Specifications and Certification Criteria Final Rule can be found at: http://www.ofr.gov/OFRUpload/OFRData/2010-17210_PI.pdf

About Eclipsys

Eclipsys is a leading provider of advanced integrated clinical, revenue cycle and performance management software, clinical content and professional services that help healthcare organizations improve clinical, financial and operational outcomes. For more information, see www.eclipsys.com or email info@eclipsys.com.

Statements in this news release concerning the implementation of and features and benefits provided by Eclipsys software, ARRA qualification, receipt of stimulus funds, and evidence-based content and services are forward-looking statements and actual results may differ from those projected due to a variety of risks and uncertainties. Implementation and client-specific configuration of Eclipsys software can be complex and time-consuming. Results depend upon a variety of factors and can vary by client. Each client’s circumstances are unique and may include unforeseen issues that make it more difficult than anticipated to implement or derive benefit from Eclipsys software or services. The success and timeliness of the company’s services will depend at least in part upon client involvement, which can be difficult to control. Eclipsys is required to meet specified performance standards, and the contract can be terminated or its scope reduced under certain circumstances. ARRA qualification requires compliance with standards that are still evolving, and satisfaction of those standards may be delayed. More information about company risks is available in recent Form 10-Q and 10-K filings made by Eclipsys from time to time with the Securities and Exchange Commission. Special attention is directed to the portions of those documents entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Eclipsys, The Outcomes Company, and Sunrise Enterprise are either registered trademarks or trademarks of Eclipsys Corporation (or its subsidiaries) in the United States and certain other countries. Other product and company names in this news release are or may be trademarks of their respective companies.

Eclipsys Corp. (MM) (NASDAQ:ECLP)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024

Eclipsys Corp. (MM) (NASDAQ:ECLP)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024